5/9
03:39 pm
olma
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its price target raised by analysts at HC Wainwright from $25.00 to $28.00. They now have a "buy" rating on the stock.
Low
Report
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its price target raised by analysts at HC Wainwright from $25.00 to $28.00. They now have a "buy" rating on the stock.
5/8
04:05 pm
olma
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/8
04:02 pm
olma
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
5/8
07:08 am
olma
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress [Yahoo! Finance]
Low
Report
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress [Yahoo! Finance]
5/8
07:02 am
olma
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
Low
Report
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
5/2
04:37 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/1
07:02 am
olma
Olema Oncology to Participate in Upcoming Investor Conferences in May
Low
Report
Olema Oncology to Participate in Upcoming Investor Conferences in May
4/10
05:23 pm
olma
FATE, ALPN and RLAY are among after hour movers [Seeking Alpha]
Medium
Report
FATE, ALPN and RLAY are among after hour movers [Seeking Alpha]
4/8
04:30 pm
olma
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
Low
Report
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
4/5
12:24 am
olma
Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
Low
Report
Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]
4/2
04:29 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/2
08:10 am
olma
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $24.00 price target on the stock.
Medium
Report
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $24.00 price target on the stock.
3/11
04:27 pm
olma
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/11
04:03 pm
olma
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
Medium
Report
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
3/6
07:12 am
olma
Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors [Yahoo! Finance]
Medium
Report
Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors [Yahoo! Finance]
3/6
07:03 am
olma
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
Medium
Report
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
3/4
04:30 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/4
05:27 am
olma
Calculating The Intrinsic Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) [Yahoo! Finance]
Medium
Report
Calculating The Intrinsic Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) [Yahoo! Finance]
2/23
06:33 am
olma
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its "overweight" rating re-affirmed by analysts at Capital One Financial Co..
Low
Report
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) had its "overweight" rating re-affirmed by analysts at Capital One Financial Co..